Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review

Abstract

Background:

Cryptogenic organizing pneumonia (COP) is an interstitial lung disease, with causes including anti-CD20 antibodies. Ocrelizumab is a humanized monoclonal antibody against CD20 approved for use in relapsing-remitting or primary progressive multiple sclerosis (MS), with no conclusive data regarding pulmonary toxicity.

Cases:

We describe two cases of COP associated with ocrelizumab use in multiple sclerosis patients.

Conclusions:

We suggest considering COP whenever respiratory symptoms arise in MS patients receiving ocrelizumab therapy. COP diagnosis requires clinical and radiological exclusion of alternative diagnoses such as opportunistic infections, autoimmunity, drugs, and neoplasms. Appropriate steroid therapy has an excellent clinical response rate.

Keywords

Organizing pneumonia drug-induced organizing pneumonia Ocrelizumab CD20 multiple sclerosis

Get full access to this article

View all access options for this article.

References

Mayer

Kappos

Racke

, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord 2019; 30: 236–243.

Montalban

Gold

Thompson

, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24: 96–120.

Lamb

. Ocrelizumab: A review in multiple sclerosis. Drugs 2022; 82: 323–334.

Kimby

. Tolerability and safety of Rituximab (MabThera). Cancer Treat Rev 2005; 31(6): 456–473.

Aysan

Köybaşı

Satıcı

, et al. Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report. Tuberk Toraks 2023; 71(1): 107–111.

Baque-Juston

Pellegrin

Leroy

, et al. Organizing pneumonia: What is it? A conceptual approach and pictorial review. Diagn Interv Imaging 2014; 95(9): 771–777.

Soubrier

Jeannin

Kemeny

, et al. Organizing pneumonia after Rituximab therapy: Two cases. Joint Bone Spine 2008; 75(3): 362–365.

Lioté

Séroussi

, et al. Rituximab-induced lung disease: A systematic literature review. Eur Respir J 2010; 35: 681–687.

Macartney

Burke

Elborn

, et al. Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin’s lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma 2005; 46(10): 1523–1526.

10.

Biehn

Kirk

Rivera

, et al. Bronchiolitis obliterans with organizing pneumonia after Rituximab therapy for non-Hodgkin’s lymphoma. Hematol Oncol 2006; 24(4): 234–237.

11.

Maeng

Chin

Yang

, et al. A case of organizing pneumonia associated with Rituximab. Cancer Res Treat 2007; 39: 88–91.

12.

Law

Kwak

Felner

, et al. Organizing pneumonia associated with Rituximab therapy for treatment of lymphoma. Chest 2012; 142: 483A.

13.

Urun

Dincol

Kumbasar

. Rituximab-related cryptogenic organizing pneumonia and late onset neutropenia in a patient with non-Hodgkin lymphoma: Report of two rare complications and review of the literature. J BUON 2012; 17(3): 602–603.

14.

Ayyad

Azar

Albandak

, et al. Rituximab-induced immune dysregulation leading to organizing pneumonia, bronchiectasis, and pulmonary fibrosis. Cureus 2023; 15: e34798.

15.

Cherian

Patel

Machnicki

, et al. Algorithmic approach to the diagnosis of organizing pneumonia: A correlation of clinical, radiologic, and pathologic features. Chest 2022; 162: 156.